ADARx Pharmaceuticals (ADRX) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NewAmsterdam Pharma N.V. is the larger company by market cap ($2.47 billion vs $1.89 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | NAMS |
|---|---|---|
| Share price | $17.70 | $21.16 |
| Market cap | $1.89B | $2.47B |
| 1-day change | +2.14% | -4.41% |
| YTD return | — | -36.92% |
| 1-year return | — | -31.29% |
| 5-year return | — | +126.05% |
| EPS (TTM) | $-1.16 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $22.50M |
| Revenue growth (YoY) | — | -50.61% |
| Net income (latest FY) | — | $-203.82M |
| Operating margin | — | -1002.90% |
| Net margin | — | -905.74% |
| 52-week high | $23.21 | $42.21 |
| 52-week low | $16.64 | $20.94 |
| Distance from 52-week high | -23.74% | -49.88% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +134.70% |
| Average volume | 1.34M | 1.35M |
| Shares outstanding | 106.80M | 116.90M |
| Employees | 100 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ADRX vs NAMS FAQ
Which is bigger, ADARx Pharmaceuticals or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.47B compared with $1.89B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.